Sensitivity, Specificity and Predictive Value of Modified Assays for Activated Protein C Resistance in Children

Greg Brandt; Ralph Gruppo; Charles J. Glueck; Davis Stroop; Ann Becker; Ann Pillow; Ping Wang

doi:10.1055/s-0037-1614946

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1998; 79(03): 567-570
DOI: 10.1055/s-0037-1614946

Review Articles

Schattauer GmbH

Sensitivity, Specificity and Predictive Value of Modified Assays for Activated Protein C Resistance in Children

Authors

Greg Brandt

¹The Division of Hematology/Oncology, S. Illinois University School of Medicine, Springfield, Illinois
Ralph Gruppo

²The Division of Hematology/Oncology, Children’s Hospital Medical Center, Cincinnati, Ohio
Charles J. Glueck

³The Cholesterol Center Jewish Hospital, Cincinnati, Ohio, USA
Davis Stroop

²The Division of Hematology/Oncology, Children’s Hospital Medical Center, Cincinnati, Ohio
Ann Becker

²The Division of Hematology/Oncology, Children’s Hospital Medical Center, Cincinnati, Ohio
Ann Pillow

²The Division of Hematology/Oncology, Children’s Hospital Medical Center, Cincinnati, Ohio
Ping Wang

³The Cholesterol Center Jewish Hospital, Cincinnati, Ohio, USA

Abstract

Summary

Very little data is available assessing the clinical utility of coagulation-based APC resistance assays compared to DNA-based analysis for the factor V Leiden mutation in children. Therefore, the clinical utility of four aPTT-based assays for APC resistance was evaluated in 169 children, ages 3 months through 16 years. The prevalence of the Arg⁵⁰⁶ to Gln mutation was 7/169 (4.1%). Using cutoff points derived from the normal PCR-screened population (n = 162), two assays for APC resistance (APC-SR and n-APC-SR) gave poor concordance with the PCR assay (sensitivity 29% and 57%, respectively). Two modified assays (FDAPC-SR and n-FDAPC-SR), in which patient plasma was prediluted 1:5 in factor V deficient plasma, gave excellent concordance (sensitivity 100%). The predictive value of a positive test was 0.25, 0.44, 1.00 and 0.88 for the APC-SR, n-APC-SR, FDAPC-SR and n-FDAPC-SR, respectively. The FDAPC-SR and n-FDAPC-SR tests gave excellent discrimination using cutoff values derived from the total population (n = 169) without regard to previous PCR screening results.

Full Text

References

References
1 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
2 Bertina RM, Koeleman BPC, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
3 Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and Factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-53.
4 Zenz W, Muntean W, Gallistl S, Leschnik B, Beitzke A. Inherited resistance to activated protein C in a boy with multiple thromboses in early infancy. Eur J Pediatr 1995; 154: 285-8.
5 Kodish E, Potter C, Kirschbaum NE, Foster PA. Activated protein C resistance in a neonate with venous thrombosis. J Pediatr 1995; 127: 645-8.
6 Zöller B, He X, Dahlbäck B. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1995; 73: 743-5.
7 Nowak-Gottl U, Koch HG, Aschka I, Kohlhase B, Vielhaber H, Kurle-mann G, Oleszcuk-Raschke K, Kehl HG, Jurgens H, Schneppenheim R. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 1996; 92: 992-8.
8 Pipe SW, Schmaier AH, Nichols WC, Ginsburg D, Bozynski ME, Castle VP. Neonatal purpura fulminans in association with factor V R506Q mutation. J Pediatr 1996; 128: 706-9.
9 Glueck CJ, Brandt G, Gruppo R, Crawford A, Roy D, Tracy T. et al. Resistance to activated protein C and Legg-Perthes disease. Clin Orthop. 1997 in press.
10 Rosen S, Johansson K, Lindbery K, Dahlbäck B. (for the APC resistance study group). Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasma from healthy individuals. Thromb Haemost 1994; 72: 255-60.
11 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
12 Dahlbäck B. Resistance to activated protein C, the Arg ⁵⁰⁶ to Gln mutation in the factor V gene, and venous thrombosis: functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995; 73: 739-42.
13 Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulant. Thromb Haemost 1995; 74: 797-8.
14 Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Letters to the Editor. Lancet 1994; 344: 1162-3.
15 Dahlbäck B. Modified APC-resistance test offers increased sensitivity and specificity for the FV:Q⁵⁰⁶ allele. Letter to the Editor. Thromb Haemost 1995; 74: 1380-1.
16 Engel H, Zwang L, van Vliet HHDM, Michiels JJ, Stibbe J, Lindermans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemost 1995; 75: 267-9.
17 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
18 Nowak-Göttl U, Kohlhase B, Vielhaber H, Aschka I, Schneppenheim R, Jüngens H. APC resistance in neonates and infants: adjustment of the APTT-based method. Thromb Res 1996; 81: 665-70.
19 Lindblom B, Holmlund G. Rapid DNA purification for restriction fragment length polymorphism analysis. Gene Anal Tech 1988; 5: 97-101.
20 Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM. et al. Complete DNA and derived amino acid sequence of human factor V. Proc Nat Acad Sci USA 1987; 84: 4846-50.
21 Koeleman PC, Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C deficient families. Blood 1994; 84: 1031-5.